carbogen

DRUG4 trials

Sponsors

Mount Vernon Cancer Centre at Mount Vernon Hospital, Stanford University, Charite University, Berlin, Germany, Yonsei University

Conditions

Acute Ischemic StrokeBladder CancerFebrile SeizureNeoplasms

Phase 1

Imaging and Biomarkers of Hypoxia in Solid Tumors

TerminatedNCT01123005

Stanford UniversityNeoplasms

Start: 2010-12-31End: 2015-08-21Updated: 2017-11-06

Phase 2

Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures

TerminatedNCT01370044

Charite University, Berlin, GermanyFebrile Seizure

Start: 2012-08-31End: 2015-06-30Updated: 2018-01-26

Phase 3

Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer

CompletedNCT00033436

Mount Vernon Cancer Centre at Mount Vernon HospitalBladder Cancer

Start: 2000-10-31End: 2008-11-30Target: 330Updated: 2013-09-20

Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)

TerminatedNCT04839224

Yonsei UniversityAcute Ischemic Stroke

Start: 2021-04-05End: 2024-09-12Updated: 2025-01-14

Related Papers

The use of carbogen for interruption of febrile seizures - the randomized controlled CARDIF trial.

2025-12-23

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.

2021-02-01106 citations

Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial.

Journal of Clinical Oncology2019-03-0114 citations

CARbon DIoxide for the treatment of Febrile seizures: rationale, feasibility, and design of the CARDIF-study.

2013-06-2712 citations